A JAMA Network Open retrospective cohort study of 125,474 adults with overweight or obesity: Patients with T2DM: 46.5% discontinued by year one 64.1% discontinued by year two Patients without T2DM: 64.8% discontinued by year one 84.4% discontinued by year two Nearly 85% of patients without diabetes stopped taking GLP-1s within two years
Its not just numbers
Taking a smaller dose every day is more effective than taking a large dose once a week
Categories such as indulgent confectionary, bakery, salty snacks and sugary beverages are already seeing pressure, with GLP-1 users demanding smaller portion sizes and reducing their snacking frequency
Thankfully, using growth hormone-releasing peptides like Sermorelin and Ipamorelin can help boost growth hormone and IGF-1 levels, thereby improving peoples health and vitality
23 As further proof of specificity and validation, we reported in the present study the results of specific GLP1R immunostaining in established human GLP1R targets such as endocrine pancreas or Brunners gland and compared these results with the data of an alternative method of GLP1R measurement, namely GLP1R autoradiography in the same tissues
